Alliancebernstein L.P. Reduces Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

Alliancebernstein L.P. reduced its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 13.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 137,424 shares of the company's stock after selling 20,781 shares during the period. Alliancebernstein L.P. owned approximately 0.34% of Keros Therapeutics worth $2,175,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Geode Capital Management LLC grew its holdings in shares of Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock worth $42,146,000 after acquiring an additional 46,041 shares during the period. SG Americas Securities LLC acquired a new stake in Keros Therapeutics in the fourth quarter valued at $388,000. Barclays PLC increased its position in shares of Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after buying an additional 35,022 shares in the last quarter. Norges Bank acquired a new position in shares of Keros Therapeutics during the 4th quarter worth $1,027,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Keros Therapeutics in the 4th quarter worth about $461,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Keros Therapeutics

In related news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This trade represents a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 22.90% of the company's stock.

Keros Therapeutics Price Performance

KROS stock traded down $0.41 during trading on Tuesday, reaching $13.89. 870,382 shares of the stock traded hands, compared to its average volume of 789,893. The business's 50 day moving average price is $11.33 and its 200-day moving average price is $28.60. The firm has a market capitalization of $563.41 million, a PE ratio of -2.67 and a beta of 1.39. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business had revenue of $3.04 million during the quarter, compared to analysts' expectations of $37.32 million. On average, equities research analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Wells Fargo & Company cut their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research report on Thursday, February 27th. Guggenheim restated a "neutral" rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Cantor Fitzgerald cut Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Piper Sandler cut their price target on Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Finally, Wedbush restated a "neutral" rating and issued a $15.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $40.33.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.